The effects of XXXX on plasma lipoproteins in @entity4310 .

@entity1 @entity294 @entity9478 @entity412 @entity5119 @entity4310 @entity165 @entity9477
During treatment with @entity5119 at the dose of 1 g per day, the mean reduction in low density lipoprotein (LDL) @entity165 concentration was 11.2% in polygenic hypercholesterolaemia (n = 9) and 9.4% in heterozygous @entity4310 (n = 6). However, there was marked heterogeneity of response: in seven of the @entity1 with polygenic hypercholesterolaemia who had in common moderate elevation of LDL @entity165 (5.3-6.4 mmol/1), the reduction ranged from 13 to 40% (mean, 23%). In two of this group the change in LDL concentration was associated with a decrease in LDL apolipoprotein B synthetic rate. Of the @entity1 with @entity4310 one showed a 33% reduction in LDL @entity165 , and one a 13% reduction. Total high density lipoprotein (HDL) @entity165 concentration tended to decrease during treatment. This reflected a reduction of the @entity165 concentration in the @entity9478 subclass; @entity9477 @entity165 remaining unchanged. Plasma @entity412 and very low density lipoprotein @entity165 were unaffected by @entity5119 . The drug was well tolerated with only one @entity1 complaining of severe @entity294 , and two of mild and transient @entity294 . No clinically significant changes occurred in serial resting electrocardiograms. Thus, @entity5119 appears to be a useful drug for the treatment of most @entity1 with polygenic hypercholesterolaemia, and of some @entity1 with heterozygous @entity4310 .
